Payload Information

General Information of This Payload

Payload ID	PAY0TZKYS
Name	Ahx-maytansine
Synonyms	Ahx-maytansine Click to Show/Hide
Target(s)	Microtubule (MT)			Target Info
Structure
Structure	3D MOL		2D MOL
Formula	C38H55ClN4O10
Isosmiles	COc1cc2cc(c1Cl)N(C)C(=O)CC(OC(=O)C(C)N(C)C(=O)CCCCCN)C1(C)OC1C(C)C1CC(O)(NC(=O)O1)C(OC)/C=C/C=C(\C)C2
InChI	InChI=1S/C38H55ClN4O10/c1-22-13-12-14-29(50-8)38(48)21-28(51-36(47)41-38)23(2)34-37(4,53-34)30(52-35(46)24(3)42(5)31(44)15-10-9-11-16-40)20-32(45)43(6)26-18-25(17-22)19-27(49-7)33(26)39/h12-14,18-19,23-24,28-30,34,48H,9-11,15-17,20-21,40H2,1-8H3,(H,41,47)/b14-12-,22-13-
InChIKey	AGSYGILVXHGQPF-VWGJIMKTSA-N
Pharmaceutical Properties	Molecule Weight	763.329	Polar area	182.49
	Complexity	53	xlogp Value	4.0336
	Heavy Count	53	Rot Bonds	10
	Hbond acc	11	Hbond Donor	3

Each Antibody-drug Conjugate Related to This Payload

Full Information of The Activity Data of The ADC(s) Related to This Payload

Trastuzumab-SYNtansine [Investigative]

ADC Info

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 80.60% (Day 23)	High HER2 expression (HER2+++)
Method Description	25 mice with T226 tumor (P12.1.4/0) between 75 and 196 mm³ were allocated, according to their tumor volume to give homogenous mean and median tumor volume in each treatment arm (5 mice/group). Treatments were initiated when the median tumor volume was 126 mm³ by intravenous injection with either vehicle (control), and trastuzumab-SYNtansine 3 mg/kg. Click to Show/Hide
In Vivo Model	Breast cancer PDX model (PDX: T226)
Experiment 2 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 23)	High HER2 expression (HER2+++)
Method Description	25 mice with T226 tumor (P12.1.4/0) between 75 and 196 mm³ were allocated, according to their tumor volume to give homogenous mean and median tumor volume in each treatment arm (5 mice/group). Treatments were initiated when the median tumor volume was 126 mm³ by intravenous injection with either vehicle (control), and trastuzumab-SYNtansine 9 mg/kg. Click to Show/Hide
In Vivo Model	Breast cancer PDX model (PDX: T226)

References

Ref 1	Enzymatic glycan remodeling-metal free click (GlycoConnect) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering. MAbs. 2022 Jan-Dec;14(1):2078466.